Antiparkinson drug use and adherence in medicare part D beneficiaries with parkinson's disease

Clinical Therapeutics

Volumn 35, Issue 10, 2013, Pages 1513-1525.e1

  Wei, Yu Jung ^a   Palumbo, Francis B ^a   Simoni Wastila, Linda ^a   Shulman, Lisa M ^b   Stuart, Bruce ^a   Beardsley, Robert ^a   Brown, Clayton ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antiparkinson drug; Medicare; Medication adherence; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE;

AGED; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CROSS-SECTIONAL STUDY; DEATH; DEPRESSION; ETHNICITY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PARKINSON DISEASE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION;

ANTIPARKINSON DRUG; MEDICARE; MEDICATION ADHERENCE; PARKINSON'S DISEASE;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MEDICARE PART D; MEDICATION ADHERENCE; PARKINSON DISEASE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84885701102     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.001     Document Type: Article

References (36)

1. Nussbaum R.L., Ellis C.E. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003, 348:1356-1364.
2. Huse D.M., Schulman K., Orsini L., et al. Burden of illness in Parkinson's disease. Mov Disord 2005, 20:1449-1454.
3. Dorsey E.R., Constantinescu R., Thompson J.P., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
4. Miyasaki J.M., Martin W., Suchowersky O., et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002, 58:11-17.
5. Setter S.M. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson's disease. Neurol Clin 2008, 26:S45-S63.
6. Bainbridge J.L., Ruscin J.M. Challenges of treatment adherence in older patients with Parkinson's disease. Drugs Aging 2009, 26:145-155.
7. Grosset D. Therapy adherence issues in Parkinson's disease. J Neurol Sci 2010, 289:115-118.
8. Huse D.M., Castelli-Haley J., Orsini L.S., et al. Patterns of initial pharmacotherapy for Parkinson's disease in the United States. J Geriatr Psychiatry Neurol 2006, 19:91-97.
9. Standaert DG, Roberson, eds. Treatment of Central Nervous System Degenerative Disorders. In: Brunton LL, ed. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011.
10. Rascol O., Goetz C., Koller W., et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002, 359:1589-1598.
11. Kulkarni A.S., Balkrishnan R., Anderson R.T., et al. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord 2008, 23:359-365.
12. Davis K.L., Edin H.M., Allen J.K. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord 2010, 25:474-480.
13. Chronic Condition Data Warehouse Part D Data User Manual. Buccaneer Computer Systems & Services, Inc. Accessed March 15, 2010. http://ccwdata.org/downloads/CCW_PartD_UserManual.pdf.
14. Safety Information-Neupro (rotigotine transdermal system). Accessed January 30, 2010. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094861.htm.
15. Pergolide (marketed as Permax) information. Accessed January 30, 2008. http://www.fda.gov/cder/drug/infopage/pergolide/default.htm.
16. Peterson A.M., Nau D.P., Cramer J.A., et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10:3-12.
17. Williams-Gray C.H., Foltynie T., Lewis S.J., Barker R.A. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 2006, 20:477-505.
18. Pope G.C., Kautter J., Ellis R.P., et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev 2004, 25:119-141.
19. Centers for Medicare & Medicaid Services (CMS). Medicare Claims Processing Manual. Chapter 18: Preventive and Screening Services. Accessed September 21, 2013. https://www.cms.gov/manuals/downloads/clm104c18.pdf.
20. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 159:702-706.
21. Fung V., Mangione C.M., Huang J., et al. Falling into the coverage gap: Part D drug costs and adherence for Medicare advantage prescription drug plan beneficiaries with diabetes. Health Serv Res 2009, 45:355-375.
22. Swarztrauber K., Koudelka C., Brodsky M.A. Initial pharmacotherapy in a population of veterans with Parkinson disease. Neurology 2006, 66:1425-1426.
23. Wei Y.J., Stuart B., Zuckerman I.H. Use of antiparkinson medications among elderly Medicare beneficiaries with Parkinson's disease. Am J Geriatr Pharmacother 2010, 8:384-394.
24. Grosset K.A., Bone I., Grosset D.G. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005, 20:1502-1507.
25. Grosset D., Taurah L., Burn D.J., et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007, 78:465-469.
26. Pahwa R., Factor S.A., Lyons K.E., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:983-995.
27. Tarrants M.L., Denarie M.F., Castelli-Haley J., et al. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 2010, 8:374-383.
28. Szumski N.R., Cheng E.M. Optimizing algorithms to identify Parkinson's disease cases within an administrative database. Mov Disord 2009, 24:51-56.
29. Swarztrauber K., Anau J., Peters D. Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data. Mov Disord 2005, 20:964-970.
30. Medicare Part D program evaluation: analysis of the impact of Medicare Part D on the FFS program and issues related to medication adherence for six chronic conditions-2007. Accessed April 16, 2012. http://www.cms.hhs.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Reports/Downloads/Ingber_MedicareDEvalComplete_2007.pdf.
31. Holmes H.M., Luo R., Hanlon J.T., et al. Ethnic disparities in adherence to antihypertensive medications of Medicare Part D beneficiaries. J Am Geriatr Soc 2012, 60:1298-1303.
32. Miyasaki J.M., Shannon K., Voon V., et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:996-1002.
33. US Preventive Services Task Force. Guide to Clinical Preventive Services, 2008: Recommendations of the US Preventive Services Task Force. Publication No. 08-05122, September 2008. Rockville, Md: Agency for Healthcare Research and Quality.
34. National Cancer Institute. Prostate-specific antigen (PSA) test. Accessed August 22, 2013. http://www.cancer.gov/cancertopics/factsheet/detection/PSA.
35. US Preventive Services Task Force Recommendation Statement March 2012. Accessed August 22, 2013. http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerrs.htm.
36. Aarsland D., Larsen J.P., Tandberg E., Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000, 48:938-942.